TICKERNERD
Menu
TNXPTNXPHealthcare · Biotechnology

TNXP Stock Forecast: Tonix Pharmaceuticals Holding Corp. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$5.28
−1.68% on the day

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. hold a median 12-month price target of $26 — +392.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$92.1M
Ticker Nerd rank
32/ 100
Median analyst target
$26
Analysts covering
4
Revenue$13.5M+577.9% y/y
Operating income−$41.9M
Net income−$40.6M
Free cash flow−$42.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.9%
1M
−45.3%
YTD
−66.2%
1Y
−71.6%
From 52W high
−73.5%
From 52W low
+2.9%
$5
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tonix Pharmaceuticals Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
32/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
84
Size
74
Quality
65
Volatility
51
Growth
41
Accruals
34
Issuance
16
Value
8
Momentum
7

Revisions (84): Analysts have, on balance, been raising their forecasts.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TNXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26TNXPHigh $65Median $26Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $18Median $26High $65

The green dot is the last close — the median target sits +392.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Oct 2026Canaccord GenuityInitiatesBuy$18
25 June 2026Raymond JamesInitiatesStrong Buy$26
25 June 2026Raymond JamesInitiatesStrong Buy—
4 May 2026TD CowenInitiatesBuy—
20 Mar 2025Noble Capital MarketsReiteratesOutperform—
22 July 2024Alliance Global PartnersMaintainsBuy—
28 Feb 2024Dawson JamesInitiatesBuy—
1 Aug 2023Alliance Global PartnersMaintainsBuy—
2 June 2023Alliance Global PartnersMaintainsBuy—
12 Jan 2023Alliance Global PartnersReiteratesBuy$6.50
18 Apr 2022Noble Capital MarketsInitiatesOutperform$0.60
31 Aug 2021Alliance Global PartnersMaintainsBuy—
11 Aug 2021Alliance Global PartnersMaintainsBuy—
25 Feb 2021Alliance Global PartnersMaintainsBuy—
18 Nov 2019B. Riley FBRDowngradeNeutral—
18 Nov 2019Cantor FitzgeraldDowngradeHold—
18 Nov 2019Janney CapitalInitiatesBuy—
18 Nov 2019OppenheimerMaintainsOutperform—
18 Nov 2019Roth CapitalUpgradeBuy—
18 Apr 2019Roth CapitalUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TNXP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TNXP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Tonix Pharmaceuticals Holding Corp. returned −71.6% against +13.1% for the S&P 500, dividends included.

TNXP vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26TNXPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TNXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Tonix Pharmaceuticals Holding Corp. (TNXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
3.2×

Cheaper than 38% of US stocks

Price / book
0.4×

Cheaper than 85% of US stocks

EV / EBITDA
0.5×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
577.9%

Higher than 98% of US stocks

Earnings growth (YoY)
577.9%

Higher than 96% of US stocks

Gross margin
94.8%

Higher than 98% of US stocks

Operating margin
−314.1%

Higher than 9% of US stocks

Net margin
49.3%

Higher than 96% of US stocks

Returns & dividend
Return on equity
−81.8%

Higher than 15% of US stocks

Return on assets
−46.8%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tonix Pharmaceuticals Holding Corp. (TNXP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tonix Pharmaceuticals Holding Corp. has a market value of $92.1M and an enterprise value of −$82.9M.

  • Revenue in the twelve months to 30 June 2026: $29.1M. The latest quarter grew 577.9% year on year.

  • Net income over the same four quarters: −$159.7M, a −548.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−12.94.

  • Free cash flow in the twelve months to 30 June 2026: −$156.1M.

  • Tonix Pharmaceuticals Holding Corp. spent $7.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 16.8M.

  • Trailing P/E: 0.1×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tonix Pharmaceuticals Holding Corp. employs 142 people — $205K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

TNXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNXPTonix Pharmaceuticals Holding Corp.$92.1M32
TNYATenaya Therapeutics, Inc.$92.0M35
NRXSNeurAxis, Inc.$93.7M67
PLYXPolaryx Therapeutics, Inc.$94.2M22
MISTMilestone Pharmaceuticals, Inc.$94.3M19
EQEquillium, Inc.$89.8M37
COYACoya Therapeutics, Inc.$95.2M67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tonix Pharmaceuticals Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNXP news & analysis

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

GlobeNewsWire · 27 Oct 2026positive

Tonix Pharmaceuticals presented an analysis of Phase 3 RELIEF and RESILIENT data at the IASP 2026 World Congress on Pain. At Week 14, TONMYA improved FIQR symptom and function scores versus placebo in both domains.

Why it matters — The presentation reports Phase 3 findings on TONMYA’s effects on fibromyalgia symptoms and function, relevant to TNXP’s marketed product.

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

GlobeNewsWire · 26 Oct 2026neutral

Tonix Pharmaceuticals announced it will report its third-quarter 2026 financial results and operational highlights during a conference call and webcast on November 9, 2026, at 8:30 a.m.

Why it matters — TNXP watchers can follow the scheduled call for the company’s quarterly financial results and operational update.

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

GlobeNewsWire · 19 Oct 2026positive

Tonix Pharmaceuticals announced that a poster analyzing TONMYA’s effects on fibromyalgia symptoms and physical function will be presented at the IASP 2026 World Congress on Pain, October 26–30 in Bangkok.

Why it matters — The presentation will share an analysis of Phase 3 data on TONMYA, a Tonix product, with attendees at an international pain congress.

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

GlobeNewsWire · 15 Oct 2026positive

Tonix Pharmaceuticals announced an oral presentation on its TNX-801 investigational vaccine platform and a company-led working group session at the World Vaccine Congress Europe, taking place in Amsterdam on October 19–21, 2026.

Why it matters — The announcement highlights planned discussion of Tonix’s vaccine platform and its work on vectored vaccine efficacy at an industry congress.

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

GlobeNewsWire · 22 Sept 2026positive

Tonix Pharmaceuticals announced a second major managed Medicare agreement for TONMYA, its treatment for fibromyalgia, effective immediately and adding approximately 21 million Medicare lives (38% of roughly 55 million U.S. Medicare lives). With this agreement, commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives, or 53% of total U.S. lives.

Why it matters — This expansion of payer coverage for TONMYA broadens patient access to the company's commercial fibromyalgia treatment across Medicare and other payers.

FAQ

Frequently asked questions about TNXP stock

What is the TNXP stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. have a median 12-month price target of $26, with estimates ranging from $18 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNXP stock a buy right now?

Of the 4 analysts covering Tonix Pharmaceuticals Holding Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tonix Pharmaceuticals Holding Corp. 32 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNXP?

As at 28 Oct 2026, Tonix Pharmaceuticals Holding Corp. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).

Will TNXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +392.4% from the last close, and Ticker Nerd's factor model ranks Tonix Pharmaceuticals Holding Corp. 32 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNXP stock forecast for 2030?

No analyst covering Tonix Pharmaceuticals Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $65 over the next 12 months.

How has TNXP stock performed over the past year?

Tonix Pharmaceuticals Holding Corp. returned -71.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tonix Pharmaceuticals Holding Corp. do?

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases.

What is the latest news on TNXP?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain". Tonix Pharmaceuticals presented an analysis of Phase 3 RELIEF and RESILIENT data at the IASP 2026 World Congress on Pain. At Week 14, TONMYA improved FIQR symptom and function scores versus placebo in both domains.

Company

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases. Tonix Pharmaceuticals Holding Corp. markets approved and late-stage products for conditions with significant unmet medical need, including TONMYA for fibromyalgia and additional medicines used in migraine care. The company’s pipeline includes programs aimed at neurological, infectious, and immune-related diseases, reflecting a broad research and development platform built around small molecules and biologics. Tonix Pharmaceuticals Holding Corp. serves the U.S. healthcare market through a combination of commercial products, clinical development programs, and disease-focused collaborations. Its role in the financial market is defined by its position as a commercial-stage biotechnology business with a diversified therapeutic portfolio and ongoing pipeline activity.

CEO Dr. Seth Lederman M.D. · 142 employees · United States · https://www.tonixpharma.com